The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity
John M. Maris(Children's Hospital of Philadelphia), Michal Zimmermann(Mount Sinai Hospital)
Cited by 1
Related Papers
Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma
|New England Journal of Medicine|2005|571
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions
|Nature|2018|415
The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models
|Clinical Cancer Research|2021|119